5-Methyl-3-Sulfanilamido-isoxazoleによる尿路感染症の治験
スポンサーリンク
概要
- 論文の詳細を見る
Experimental and clinical studies of a new sulfon a m ide, 5-Methyl-3-Sulfanilamido-isoxazole, have been undertaken. Maintenance of the effective concentration of this drug in the blood stream has been found to be relatively longer according to measurement of its concentration in the blood and urinary excretion. This drug has been employed to fourty four patients mainly consisted of acute or chronic cystitis and urethritis and it is found that this drug is as effective as other sulfonamides. Unlike others satisfactory effect can be obtained with doses of 1-2 gm only twice daily and thus frequent administrations are not required. Furthermore no additional fluid and alkalizing therapies are required to prevent acidificaiion of urine. Only side effect encountered was in three out of forty four patients.
- 泌尿器科紀要刊行会の論文
泌尿器科紀要刊行会 | 論文
- MVAC療法後の転移性尿路上皮癌に対するGemcitabine, Docetaxel, Carboplatin併用化学療法の検討
- Grade 3 Ta-1表在性膀胱癌に対する膀胱温存治療
- 腹腔鏡下に摘出した後腹膜神経線維腫の1例
- 移植腎生検による腎内動脈瘤破裂の1例
- Modified M-VAC療法後に残存腫瘍切除を施行した進行尿路上皮癌患者の治療成績